Thalidomide Celgene Corp.

Area of Science:

• Immunology and Pharmacology
• Oncology and Infectious Diseases

Background:

• Thalidomide inhibits elevated tumor necrosis factor-alpha (TNFalpha), suggesting therapeutic potential across various inflammatory and autoimmune conditions.
• Approved for erythema nodosum leprosum, thalidomide is being investigated for a spectrum of diseases including HIV/AIDS complications, rheumatoid arthritis, and cachexia.

Purpose of the Study:

• To evaluate thalidomide's efficacy in treating chronic autoimmune disorders like Behcet's disease and aphthosis.
• To assess thalidomide's impact on aphthous ulcerations in HIV-infected patients.
• To determine thalidomide's effectiveness in managing AIDS-related cachexia and chronic diarrhea in HIV patients.

Main Methods:

• Clinical trials involving randomized, double-blind, placebo-controlled designs with varying doses of thalidomide.
• Phase II and III trials assessed outcomes such as ulcer reduction, body weight changes, diarrhea occurrence, and disease markers.
• Studies included patient populations with HIV/AIDS, leprosy complications, rheumatoid arthritis, and cancer-related cachexia.

Main Results:

• Thalidomide significantly reduced existing ulcerations and inhibited new lesion formation in Behcet's disease and aphthosis trials.
• In AIDS-related cachexia, thalidomide (100 mg dose) significantly increased body weight, but higher doses led to side effects and initial viral load increase.
• A trial for chronic diarrhea in HIV patients showed a reduction in diarrhea occurrence with thalidomide treatment.

Conclusions:

• Thalidomide demonstrates significant therapeutic benefits for specific inflammatory and autoimmune conditions, including ulcerations and cachexia.
• Careful dose selection and monitoring are crucial due to potential side effects and impact on viral load in HIV patients.
• Further research is warranted to optimize thalidomide's use in managing complex diseases like HIV/AIDS and rheumatoid arthritis.